Skip to main content
SpringerLink
Log in

Pharmaceutical Pricing in Europe

  • Chapter
  • First Online:
Book cover Pharmaceutical Prices in the 21st Century

Abstract

How are medicine prices decided upon in European countries? Which challenges do policy makers face? Which role do reimbursement aspects play in the pricing process? Are there communalities and similarities between European countries? This chapter provides information on pharmaceutical pricing policies in 30 European countries, including all 28 European Union Member States. Key pricing policies at ex-factory price level as well as in the supply chain will be presented. Medicine price data will be provided as an illustrative snapshort.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuoliene K, Haycox A, Garattini S, Gustafsson LL (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 10:153. doi:10.1186/1472-6963-10-153

    Article  Google Scholar 

  • Andert R, Schröder Y (2011) Local payers versus global players. Soziale Sicherheit 5:257–261

    Google Scholar 

  • Ball D (2011) The regulation of mark-ups in the pharmaceutical supply chain. Working paper 3, WHO/HAI project on medicine prices and availability

    Google Scholar 

  • Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, Malmström R, Vogler S, Godman B, Gustafsson L (2013) Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 69(1):73–78. doi:10.1007/s00228-013-1497-5

    Article  Google Scholar 

  • Bouvy J, Vogler S (2013) Background paper 8.3 pricing and reimbursement policies: impacts on innovation. In: World Health Organization (ed) Priority medicines for Europe and the World. “A public health approach to innovation”. Update on 2004 Background Paper

    Google Scholar 

  • Brekke KR, Holmås TH, Straume OR (2010) Are pharmaceuticals still inexpensive in Norway? A comparison of prescription drug prices in ten European countries. SNF report no. 08/10

    Google Scholar 

  • Bundesministerium für Gesundheit (2008) Regelung für die Vorgehensweise der Preiskommission bei der Ermittlung des EU-Durchschnittspreises gemäß § 351c Abs. 6 ASVG

    Google Scholar 

  • Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373(9659):240–249

    Article  Google Scholar 

  • Danzon PM, Wang YR, Wang L (2005) The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s. Health Econ 14(3):269–292

    Article  Google Scholar 

  • Department of Health (2013) The pharmaceutical price regulation scheme 2014. Guidance

    Google Scholar 

  • The Council of the European Communities Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems

    Google Scholar 

  • EFPIA (2013) The pharmaceutical industry in figures—edition 2013. European Federation of Pharmaceutical Industries and Associations, Brussels

    Google Scholar 

  • ESIP, AIM (2011) Review of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems (Transparency Directive). Joint Position Paper. Submitted by European Social Insurance Platform (ESIP)/Association Internationale de la Mutualité (AIM) on 10 February 2011

    Google Scholar 

  • Espín J, Rovira J, García L (2011) Experiences and impact of European risk-sharing schemes focusing on oncology medicines. EMINet, Vienna

    Google Scholar 

  • Festöy H, Aanes T, Yu L-M, Ognøy AH, Gregersen T (2011) PHIS pharma profile Norway. Pharmaceutical Health Information System (PHIS), Vienna

    Google Scholar 

  • Gallini A, Legal R, Taboulet F (2012) The influence of drug use in university hospitals on the pharmaceutical consumption in their surrounding communities. Br J Clin Pharmacol 7(10):1365–2125

    Google Scholar 

  • Gesundheit Österreich GmbH Pharma Price Information (PPI) service. Further information available from http://www.goeg.at/en/PPI. Vienna

  • Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J, Hensjö L-O, Hjemdahl P, Jägre I, Julander M, Ringertz B, Schmidt D, Sjöberg S, Sjöqvist F, Stiller C-O, Törnqvist E, Tryselius R, Vitols S, von Bahr C, Regional Drug Expert Consortium (2011) The ‘Wise List’—a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 108(4):224–233. doi:10.1111/j.1742-7843.2011.00682.x

    Article  Google Scholar 

  • Habl C, Vogler S, Leopold C, Schmickl B, Fröschl B (2008) Referenzpreissysteme in Europa. Analyse und Umsetzungsvoraussetzungen für Österreich [Reference price systems in Europe. Analysis and lessons learned for implementation in Austria]. ÖBIG Forschungs- und Planungsgesellschaft mbH, Vienna

    Google Scholar 

  • Herms S, Rutledge P (2002) The Lothian Joint Formulary: overcoming the barriers to formulary success. Pharm Pract 12(6):279–285

    Google Scholar 

  • Hoebert J, Mantel-Teuwisse A (2011) PHIS evaluation report. Pharmaceutical Health Information System (PHIS), Utrecht

    Google Scholar 

  • Hogerzeil HV (2004) The concept of essential medicines: lessons for rich countries. BMJ 329(7475):1169

    Article  Google Scholar 

  • Hogerzeil HV (2006) Essential medicines and human rights: what can they learn from each other? Bull World Health Organ 84(5):371–375

    Article  Google Scholar 

  • Hogerzeil HV, Samson M, Casanovas JV, Rahmani-Ocora L (2006) Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts? Lancet 368(9532):305–311

    Article  Google Scholar 

  • Husereau DR, Cameron CG, Foundation CHSR (2011) Value-based pricing of pharmaceuticals in Canada: opportunities to expand the role of health technology assessment? Canadian Health Services Research Foundation, Ottawa

    Google Scholar 

  • Kanavos PG, Vandoros S (2011) Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law 6(3):337

    Article  Google Scholar 

  • Kanavos P, Schurer W, Vogler S (2011a) Pharmaceutical distribution chain in the European Union: structure and impact on pharmaceutical prices. EMINet, Vienna

    Google Scholar 

  • Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M (2011b) Differences in costs of and access to pharmaceutical products in the EU. European Parliament, Brussels

    Google Scholar 

  • Karanikolos M, Mladovsky P, Cylus J, Thomson S, Basu S, Stuckler D, Mackenbach JP, McKee M (2013) Financial crisis, austerity, and health in Europe. Lancet 381(9874):1323–1331

    Article  Google Scholar 

  • KELA (2013) Finland. Recent changes in pharmaceutical policy measures and developments in pharmaceutical expenditure. Paper presented at the poster for the PPRI Network Meeting, London, March 2013

    Google Scholar 

  • Kyle MK (2007) Pharmaceutical price controls and entry strategies. Rev Econ Stat 89(1):88–99

    Article  Google Scholar 

  • Leopold C, Vogler S (2010) Access to essential medicines in Romania Vienna

    Google Scholar 

  • Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R (2012) Differences in external price referencing in Europe—a descriptive overview. Health Policy 104(1):50–60. doi:10.1016/j.healthpol.2011.09.008

    Article  Google Scholar 

  • Leopold C, Mantel-Teeuwisse AK, Vogler S, de Joncheere K, Laing RO, Leufkens HGM (2013) Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy 112:209–216. doi:10.1016/j.healthpol.2013.08.012

    Article  Google Scholar 

  • Levison L, Laing R (2003) The hidden costs of essential medicines. Essent Drugs Monitor 33:20–21

    Google Scholar 

  • Lopes S, Marty C, Berdai D (2011) PHIS pharma profile France. Pharmaceutical Health Information System (PHIS), Vienna

    Google Scholar 

  • Martinez V, Ferré de la Peña P, Izquierdo G, Lens Cabrera C (2010) PHIS pharma profile Spain. Pharmaceutical Health Information System (PHIS), Vienna

    Google Scholar 

  • Mladovsky P, Srivastava D, Cylus J, Karanikolos M, Evetovits T, Thomson S, McKee M (2012) Health policy responses to the financial crisis in Europe. Policy summary Dänemark

    Google Scholar 

  • OECD (2008) Pharmaceutical pricing policies in a global market. OECD health policy studies. OECD, Paris

    Book  Google Scholar 

  • OECD (2014) OECD health data. OECD, Paris

    Google Scholar 

  • Paris V, Belloni A (2013) Value in pharmaceutical pricing. OECD health working papers, no. 63. OECD Publishing, Paris

    Google Scholar 

  • PPRI Network Members (2007-2014a) PPRI/PHIS pharma profiles—country specific reports on pharmaceutical systems and policies. http://whocc.goeg.at/Publications/CountryReports. Vienna

  • PPRI Network Members (2007-2014b) PPRI/PHIS posters—country specific information on different issues related to pharmaceutical systems and policies. Pharmaceutical Pricing and Reimbursement Information (PPRI)/Pharmaceutical Health Information System (PHIS), Vienna. http://whocc.goeg.at/Publications/CountryPosters

  • PPRI Network Members (2014) PPRI network query on generic price link (unpublished compilation). Pharmaceutical Pricing and Reimbursement Information (PPRI), Vienna

    Google Scholar 

  • PPRI Secretariat (2014a) PPRI/PHIS database, update 2014. Pharmaceutical Pricing and Reimbursement Information (PPRI)/Pharmaceutical Health Information System (PHIS), Vienna

    Google Scholar 

  • PPRI Secretariat (2014b) PPRI/PHIS database, update 2014. Pharmaceutical Pricing and Reimbursement Information (PPRI)/Pharmaceutical Health Information System (PHIS), Vienna

    Google Scholar 

  • Redman T, Köping Höggärd M (2007) PPRI pharma profile Sweden. Pharmaceutical Pricing and Reimbursement Information (PPRI), Vienna

    Google Scholar 

  • Schröder-Bernhardi D, Dietlein G (2002) Lipid-lowering therapy: do hospitals influence the prescribing behavior of general practitioners? Int J Clin Pharmacol Ther 40(7):317–321

    Article  Google Scholar 

  • Seiter A (2010) A practical approach to pharmaceutical policy. World Bank Publications, Washington, DC

    Book  Google Scholar 

  • Stuckler D, Basu S, Suhrcke M, Coutts A, McKee M (2011) Effects of the 2008 recession on health: a first look at European data. Lancet 378(9786):124–125

    Article  Google Scholar 

  • Stuffken R (2011) Medication changes in patients transitioning between health care settings. Utrecht University, Utrecht

    Google Scholar 

  • Teixeira I, Vieira I (2008) PPRI pharma profile Portugal. Pharmaceutical Pricing and Reimbursement Information (PPRI), Vienna

    Google Scholar 

  • The World Bank (2014) How we classify countries. http://data.worldbank.org/about/country-classifications/country-and-lending-groups. Accessed 20 May 2014

  • Vogler S (2012a) How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia Health Econ Ther Pathways 13(Suppl 3):29–41

    Google Scholar 

  • Vogler S (2012b) The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries—an overview. GaBI J 1(2):93–100. doi:10.5639/gabij.2012.0102.020

    Article  Google Scholar 

  • Vogler S (2012c) Preisbildung und Erstattung von Arzneimitteln in der EU—Gemeinsamkeiten, Unterschiede und Trends. Pharm Med 14(1):56

    Google Scholar 

  • Vogler S (2014) Liberalization in the pharmacy sector. OECD global forum on distribution. OECD, Paris

    Google Scholar 

  • Vogler S, Habl C, Leopold C, Rosian-Schikuta I, de Joncheere K, Lyager Thomsen T (2008) PPRI report. Pharmaceutical Pricing and Reimbursement Information, Vienna

    Google Scholar 

  • Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N (2010) PHIS Hospital Pharma Report. Pharmaceutical Health Information System (PHIS); commissioned by the European Commission and the Austrian Federal Ministry of Health, Vienna

    Google Scholar 

  • Vogler S, Habl C, Bogut M, Voncina L (2011a) Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J 52(2):197

    Article  Google Scholar 

  • Vogler S, Zimmermann N, Leopold C, de Joncheere K (2011b) Pharmaceutical policies in European countries in response to the global financial crisis. South Med Review 4(2):32

    Article  Google Scholar 

  • Vogler S, Zimmermann N, Leopold C, Schmickl B, Windisch F (2011c) Impact of medicines price reductions in Greece and Spain on other European countries applying external price referencing. Poster. Paper presented at the drug utilisation and health policy meeting, Antwerp, 30 May 2012

    Google Scholar 

  • Vogler S, Sandberger K, Arts D, Habl C (2012a) OTC medicines—distribution in Europe. EMINet, Vienna

    Google Scholar 

  • Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A (2012b) Discounts and rebates granted to public payers for medicines in European countries. South Med Rev 5(1):38–46

    Google Scholar 

  • Vogler S, Zimmermann N, Habl C, Leopold C, Dolinar E (2013a) Survey about interface management measures regarding medication. Poster at the EAHP (European Association of Hospital Pharmacists) Congress, Paris, 13–15 March 2013

    Google Scholar 

  • Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J (2013b) Discounts and rebates granted for medicines for hospital use in five European countries. Open Pharmacoecon Health Econ J 5:1–10. doi:10.2174/1876824520130426001

    Article  Google Scholar 

  • Vogler S, Leopold C, Zimmermann N, Habl C, de Joncheere K (2014a) The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative—experiences from engaging with pharmaceutical policy makers. Health Policy Technol 3(2):139–148. doi:10.1016/j.hlpt.2014.01.001

    Article  Google Scholar 

  • Vogler S, Pertl D, Schmickl B, Windisch F (2014b) Apothekenhonorierung in Europa [Pharmacy remuneration in Europe]. Gesundheit Österreich Forschungs- und Planungsgesellschaft mbH, Vienna

    Google Scholar 

  • WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (2013) Glossary of pharmaceutical terms. Update 2014. Vienna

    Google Scholar 

  • WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (2014) Pharmaceutical policy monitoring exercise with national competent authorities represented in the PPRI (Pharmaceutical Pricing and Reimbursement Information) network. Bi-annually, latest update: February 2014 (unpublished)

    Google Scholar 

  • World Health Organization (2004) Equitable access to essential medicines: a framework for collective action. WHO policy perspectives on medicines

    Google Scholar 

Download references

Acknowledgements

We thank the members of the Pharmaceutical Pricing and Reimbursement Information (PPRI) network for providing on a regular basis over several years information about pricing and reimbursement policies in their country. We appreciate that they validated the correctness and up-to-dateness of country-specific data and information used in this section.

Furthermore, we are grateful to the Pharma Price Information (PPI) team at Gesundheit Österreich GmbH for sharing medicine price data to allow for illustrative examples.

Author information

Authors and Affiliations

  1. Health Economics Department, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Gesundheit Österreich GmbH/Geschäftsbereich ÖBIG—Austrian Health Institute, Vienna, Austria

    Sabine Vogler

  2. Research Department, Social Insurance Institution (Kela), Helsinki, Finland

    Jaana E. Martikainen

Authors
  1. Sabine Vogler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaana E. Martikainen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabine Vogler .

Editor information

Editors and Affiliations

  1. Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

    Zaheer-Ud-Din Babar

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Vogler, S., Martikainen, J.E. (2015). Pharmaceutical Pricing in Europe. In: Babar, ZUD. (eds) Pharmaceutical Prices in the 21st Century. Adis, Cham. https://doi.org/10.1007/978-3-319-12169-7_19

Download citation

Publish with us

Policies and ethics

Search

Navigation